Bora Biologics, a subsidiary of Tanvex Biopharma born out of a spinoff from Bora Pharmaceuticals, is expanding CDMO operations at its San Diego facility.
The new project will add 8,075 square feet of production to the site.
The additions will include a pair of 2,000-liter bioreactors and design plans that will accommodate future bioreactor expansion of up to 5,000 liters, Bora Biologics said in a May 20 press release.
Costs associated with the expansion weren’t disclosed.
“With this expansion, we will be able to offer our customers 2000L commercial capacity with the ability to purify modern high-titer cell culture processes,” John Mosack, Bora’s GM and VP of operations in San Diego, said in the release.
Tanvex completed its acquisition of Bora’s CDMO business in January. In August last year, Bora Pharma took a 30.5% stake in fellow Taiwanese drugmaker Tanvex, which then rolled Bora’s CDMO business into its operations and rebranded the subsidiary as Bora Biologics.
As part of that deal, Bora picked up Tanvex’s production facility in San Diego.
Prior to the Tanvex deal, Bora Pharma was already on a tear to expand in the CDMO segment.
In June of 2024, Bora spent $30 million to acquire Emergent BioSolutions' fill-finish drug product facility in Baltimore. That deal followed the January 2024 acquisition of Minnesota generics manufacturer Upsher-Smith Laboratories for $210 million, which gave Bora its first presence in the U.S.
In 2022, Bora purchased fellow Taiwanese company TWi Pharmaceuticals, picking up two manufacturing facilities, and it also bought Eden Biologics' CDMO business.